By E. Janene Geiss
Philadelphia, Oct. 25 - Marinus Pharmaceuticals, Inc. said it raised $29.4 million in a series A financing round.
Lead investors were Domain Associates, Sofinnova Ventures and Canaan Partners with participation by Foundation Medical Partners and private investors.
The financing will be used primarily for the in-licensing and development of clinical stage drugs to treat neurological, psychiatric and pain disorders, according to a company news release.
"We believe that Marinus has the opportunity to become a leader in developing new therapies to treat serious CNS disorders," said Nicole Vitullo, a partner at Domain Associates, in a news release
Vitullo, Nicola Campbell of Sofinnova Ventures and Stephen Bloch of Canaan Partners will join Harry H. Penner Jr., chairman and chief executive officer of Marinus, on the company's board of directors, officials said.
Marius is a Branford, Conn.-based pharmaceutical company focused on drug development for neurological, psychiatric and pain disorders.
| Issuer: | Mariner Pharmaceuticals Inc.
|
| Issue: | Series A financing
|
| Amount: | $29.4 million
|
| Investors: | Domain Associates, Sofinnova Ventures, Canaan Partners (leads), Foundation Medical Partners, private investors
|
| Announcement date: | Oct. 25
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
